A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.
BACKGROUND
Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness. The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness by head pain.


METHODS
Using randomized double-blind, placebo-controlled methodology, 10 females, 6 with migrainous vertigo (V+) and four without vertigo (V-) received 10 mg rizatriptan or placebo two hours prior to being stimulated by optokinetic stripes. Visual stimulation was coupled with three pain conditions: no pain (N), thermally-induced hand pain (H) and temple pain (T). Motion sickness and subjective discomfort were measured.


RESULTS
Motion sickness was less after pre-treatment with rizatriptan for 4 of 10 subjects and more for 5 of 10 subjects. Augmentation of motion sickness by head pain was seen in 6 of 10 subjects; this effect was blunted by rizatriptan in 4 of these 6 subjects. Subjective discomfort was significantly more noticeable in V+ subjects as compared with V- subjects.


CONCLUSIONS
These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Furman
Joseph M
JM
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA. furman@pitt.edu
Marcus
Dawn A
DA
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy*; D009041:Motion Sickness / Q000150:complications* / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan
Eur J Pharmacol. 1997 Jun 5;328(1):37-40
9203565
Exp Brain Res. 2008 Sep;190(2):165-77
18566806
Audiol Neurootol. 2008;13(2):113-22
18057875
Brain Res Bull. 1998 Nov 15;47(5):395-406
10052567
Eur J Pharmacol. 1994 Feb 21;253(1-2):53-60
8013549
Headache. 2001 Jun;41(6):604-5
11437901
Cephalalgia. 2008 Sep;28(9):988-90
18624802
Expert Opin Pharmacother. 2005 Dec;6(15):2691-7
16316307
Aerosp Med. 1968 May;39(5):453-5
5648730
Br J Pharmacol. 1995 Mar;114(5):931-4
7780647
Headache. 2007 Nov-Dec;47(10):1427-35
18052952
Headache. 2001 Sep;41(8):754-63
11576198
Brain. 1984 Dec;107 ( Pt 4):1123-42
6334543
Drugs. 2005;65(18):2557-67
16392873
Cephalalgia. 2002 Mar;22(2):117-24
11972579
Cephalalgia. 2002 May;22(4):271-81
12100089
Headache. 1981 Sep;21(5):227-31
7287423
Neurology. 2006 Sep 26;67(6):1028-33
17000973
Brain. 2004 Mar;127(Pt 3):526-34
14749288
J Headache Pain. 2008 Jun;9(3):185-8
18427727
Neuroscience. 1993 Feb;52(4):941-9
8450981
Med Sci Monit. 2004 May;10(5):CR197-201
15114269
Brain Res Brain Res Rev. 1995 Jan;20(1):24-46
7711766
Neurology. 2001 Feb 27;56(4):436-41
11222783
Nat Med. 1995 Jul;1(7):658-60
7585147
Exp Brain Res. 2007 Apr;178(4):477-87
17256169
Med Sci Monit. 2006 Jan;12(1):PI1-7
16369474
Cochrane Database Syst Rev. 2004;(3):CD002851
15266468
Headache. 2004 Apr;44(4):328-32
15109357
Physiol Behav. 2002 Dec;77(4-5):469-75
12526985
Expert Rev Neurother. 2005 Sep;5(5):597-603
16162083
Drugs. 2002;62(10):1539-74
12093318
Cephalalgia. 2004;24 Suppl 1:9-160
14979299
Expert Opin Pharmacother. 2003 Oct;4(10):1709-15
14521481
J Vestib Res. 2005;15(5-6):327-32
16614477
Headache. 2005 Jun;45(6):653-6
15953297
Aviat Space Environ Med. 1999 Nov;70(11):1077-80
10608604
Cephalalgia. 2008 Jan;28(1):72-7
17999681
Pharmacol Biochem Behav. 2002 Nov;73(4):979-89
12213545